Table 1.
Patient characteristics in both study groups and average dosages during run-in phase and treatment phase in both groups
| Treatment Group | Methadone (METH) | LAAM | |
|---|---|---|---|
| Total number (n) | 22 | 31 | |
| Gender | 12 F/10 M | 11 F/20 M | |
| Age (avg) | 31.0 yrs | 27.9 yrs | |
| Average dosage during run-in period (METH in both groups) | 72.0 ± 25.5 mg daily | 73.5 ± 25.7 mg daily | |
| Average dosage during treatment phase | 69 ± 27.6 mg METH | Mon & Wed | Fri |
| 89.6 ± 32.4 mg LAAM | 109.7 ± 39.5 mg LAAM | ||
| equiv. to 68.9 ± 24.9 mg METH* | equiv. to 68.6 ± 24.7 mg METH* | ||
*For better comparability, METH equivalents are shown in the LAAM groups assuming a factor of 1.3 (Monday & Wednesday) and 1.6 (Friday).